Guangzhou Xinhongrui Investment Consulting Partnership (Limited Partnership), Guangzhou Xinhongyu Investment Consulting Partnership (Limited Partnership), Guangzhou Xinhongyu Investment Consulting Partnership (Limited Partnership) and Xie Jiangtao agreed to acquire 72% stake in Guangzhou Jinli Pharmaceutical Technology Co., Ltd. from Guangzhou Kingmed Diagnostics Group Co., Ltd. for CNY 220 million on August 11, 2023. The deal has been approved by board of directors and is still subject to approval from Guangzhou Kingmed Diagnostics Group. As of March 31, 2023, Guangzhou Jinli Pharmaceutical Technology reported total assets of CNY 70 million and net assets of CNY 21.6 million.

As of August 29, 2023, Guangzhou Kingmed Diagnostics Group Co., Ltd. shareholders approved the transaction at ESM held on August 28, 2023.